Neratinib, marketed under the name Nerliden, is an anti-tumor drug also known as a thyroid hormone antagonist, a tyrosine metabolite inhibitor and an amino acid inhibitor that are useful in the treatment of various forms of cancer. It is one of the promising drugs that has undergone several clinical trials for its potential effectiveness against pancreatic cancer, liver cancer, ovarian cancer, renal cell cancer, prostate cancer and lung cancer. It is believed to be capable of preventing the growth of tumors in human pre-existing renal cell carcinoma. Further studies are underway to evaluate its effect in blocking the growth and spread of leukaemia cells in humans.
In the clinical trial conducted by the National Institute of Cancer, it was proved that Neratinib at https://www.aasraw.com/products/neratinib/ is able to improve the overall survival of patients who were treated with combination therapy with gemcitabine, paclitaxel, bleomycin and carboplatinum. Overall survival was noted to be better in the group given Neratinib than in the placebo group. The investigators attributed this improvement to the combination of antineoplastic. However, they emphasized that the results must be verified in other ongoing clinical trials.
The Food and Drug Administration or FDA had conducted some tests on the safety of Neratinib in patients with benign prostatic hyperplasia, benign kidney disease and urinary tract infections. A report on this study concluded that there were no incidents of severe or dangerous effects. However, patients must be cautious in the use of Neratinib if they suffer from frequent diarrhea or vomiting since its efficacy has not been established in these cases. They must be under strict supervision of a doctor when using Neratinib. Patients suffering from renal failure and chronic kidney problems such as kidney tumor or nephrotuberculosis must not use Neratinib.
One of the objectives of the present study is to assess the efficacy of Neratinib in the treatment for women with hormone receptor-positive breast cancer and chemotherapy-induced nausea and vomiting. Accordingly, women who have not responded adequately to prior hormonal therapy are randomly assigned to receive either placebo or norepinephrine ion channel blocker (Nutra-Bank). Women who do not respond to initial hormonal therapy are also treated with the combination of norepinephrine and a combination of gemcitabine, paclitaxel, bleomycin and carboplatinum. In this case, the investigators also examined the role of vitamin C and selenium on the efficacy of Neratinib.
Before starting to take any medication like Erlotinib, it is important to consult a doctor. A pharmacist can assist you greatly in deciding the dosage of drugs, the contraindications and precautions related to the medication and the possibility of effects. It is important to obtain medical histories of patients before starting any complementary or alternative medicines.
Like all drugs, the safety of Neratinib is dependent upon proper dosing. It should not be used by persons with hypoglycemia. It should not be used with chemotherapy or radiation therapy, or with any other medication that is known to cause a pronounced sedative effect. In addition, if one has a history of depression, seizure disorders or a psychiatric illness such as bipolar disorder, the medication should be discontinued.